{"organizations": [], "uuid": "66fd937db519b24c6fbc863fb6a70662e313940a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180201.html", "section_title": "Archive News &amp; Video for Thursday, 01 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-granted-alnylams-request-for-p/brief-fda-granted-alnylams-request-for-priority-review-idUSASB0C3MO", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Granted Alnylam's Request For Priority Review", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.164, "site_type": "news", "published": "2018-02-02T05:21:00.000+02:00", "replies_count": 0, "uuid": "66fd937db519b24c6fbc863fb6a70662e313940a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-granted-alnylams-request-for-p/brief-fda-granted-alnylams-request-for-priority-review-idUSASB0C3MO", "ord_in_thread": 0, "title": "BRIEF-FDA Granted Alnylam's Request For Priority Review", "locations": [], "entities": {"persons": [], "locations": [{"name": "patisiran", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "request for priority review feb", "sentiment": "negative"}, {"name": "alnylam", "sentiment": "negative"}, {"name": "alnylam pharmaceuticals inc", "sentiment": "negative"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 1 (Reuters) - Alnylam Pharmaceuticals Inc:\n* ALNYLAM ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRIORITY REVIEW STATUS FOR PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS\n* ALNYLAM PHARMACEUTICALS INC - FDA ALSO GRANTED COMPANY‘S REQUEST FOR PRIORITY REVIEW AND HAS SET AN ACTION DATE OF AUGUST 11, 2018\n* ALNYLAM PHARMACEUTICALS INC - ‍AT THIS TIME, FDA IS NOT PLANNING TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-02T05:21:00.000+02:00", "crawled": "2018-02-02T12:43:08.035+02:00", "highlightTitle": ""}